Alok Tayi

May 1, 2023 | outsourcedpharma.com | Ed White |Alok Tayi |Yves Massicotte |Louis Garguilo

By Ed White, Clarivate Clarivate has published its 2023 list of the Top 100 Global Innovators, identifying the companies and institutions globally that have pushed the boundaries of technology and applied knowledge the furthest. To define “innovation” in this context, Clarivate uses global invention data, which includes patent applications and issued/granted patents.

May 1, 2023 | outsourcedpharma.com | Peter Alexander |Thomas Harrington |Ed White |Alok Tayi |Louis Garguilo

Article | By Alok Tayi, Ph.D., Egnyte Drug development has dramatically changed over the past ten years. A practice once dominated by pen and paper has since been overrun by computerized systems, cloud software, and artificial intelligence. In this piece, we will chronicle recent technological trends, specific challenges these trends pose for quality and CSV teams, and best practices for tackling resulting compliance issues.

May 1, 2023 | outsourcedpharma.com | Ed White |Alok Tayi |John Baumann |Yves Massicotte |Louis Garguilo

By Ed White, Clarivate Clarivate has published its 2023 list of the Top 100 Global Innovators, identifying the companies and institutions globally that have pushed the boundaries of technology and applied knowledge the furthest. To define “innovation” in this context, Clarivate uses global invention data, which includes patent applications and issued/granted patents.

May 1, 2023 | outsourcedpharma.com | Peter Alexander |Thomas Harrington |Ed White |Alok Tayi |Louis Garguilo

Article | By Alok Tayi, Ph.D., Egnyte Drug development has dramatically changed over the past ten years. A practice once dominated by pen and paper has since been overrun by computerized systems, cloud software, and artificial intelligence. In this piece, we will chronicle recent technological trends, specific challenges these trends pose for quality and CSV teams, and best practices for tackling resulting compliance issues.

Feb 15, 2023 | outsourcedpharma.com | Louis Garguilo |Miriam Guest |Alok Tayi

By Louis Garguilo, Chief Editor, Outsourced Pharma If cell therapy is the art of engineering, the  of these therapies – many of which are stymied by an inability to scale up or produce at various locations  –is fully contingent upon the application of engineering concepts and practices. Part two of our look into "cell therapy industrialization."